Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBT Margin: 2017-2025

Historic EBT Margin for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to 14.03%.

  • Organogenesis Holdings' EBT Margin rose 897.00% to 14.03% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.33%, marking a year-over-year increase of 193.00%. This contributed to the annual value of -0.58% for FY2024, which is 298.00% down from last year.
  • Latest data reveals that Organogenesis Holdings reported EBT Margin of 14.03% as of Q3 2025, which was up 219.71% from -11.72% recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' EBT Margin ranged from a high of 17.19% in Q2 2021 and a low of -29.74% during Q1 2025.
  • Moreover, its 3-year median value for EBT Margin was -1.80% (2023), whereas its average is -1.88%.
  • In the last 5 years, Organogenesis Holdings' EBT Margin soared by 3,626bps in 2021 and then plummeted by 2,579bps in 2025.
  • Organogenesis Holdings' EBT Margin (Quarterly) stood at 14.77% in 2021, then crashed by 720bps to 7.58% in 2022, then plummeted by 938bps to -1.80% in 2023, then spiked by 990bps to 8.10% in 2024, then skyrocketed by 897bps to 14.03% in 2025.
  • Its EBT Margin was 14.03% in Q3 2025, compared to -11.72% in Q2 2025 and -29.74% in Q1 2025.